Biobeat Names Raymond W. Cohen Chairman of the Board

Biobeat Applied sciences Ltd, a medical system firm that has developed a wearable cuff-less ambulatory blood strain monitoring system that data and analyzes quite a few physiological parameters, at the moment introduced the appointment of Raymond W. Cohen as its Chairman of the Board of Administrators.

Biobeat developed and has obtained FDA clearance for an easy-to-apply “patch” system that may accumulate, document and transmit affected person knowledge to a cloud-based knowledge middle for AI-aided evaluation and reporting of physiological parameters, together with steady cuff-less ambulatory blood strain (ABPM), Sp02, respiration price, pulse price, coronary heart price variability, ECG, temperature and cardiac output.

“We welcome Raymond W. Cohen as our new Chairman,” mentioned Arik Ben Ishay, co-founder and CEO of Biobeat. “Ray’s intensive observe document in main, financing and scaling medical expertise corporations will probably be invaluable as we glance to capitalize on our distinctive ambulatory expertise.”

Mr. Cohen, an accredited public firm director and completed medical expertise govt, has over 4 a long time of life science business expertise. He was the co-founder and CEO of publicly traded Axonics, Inc., a worldwide chief in implantable neuromodulation units that accomplished its preliminary public providing in late 2018. Underneath his management, Axonics generated over $1 billion in income inside 4 years of its business launch, grew to become worthwhile, earned recognition because the fastest-growing expertise firm in North America, and was acquired by Boston Scientific in November 2024 for $3.7 billion. In March 2025, Mr. Cohen, as chairman of SoniVie, Ltd., an Israeli scientific stage renal denervation firm, led the sale of SoniVie to Boston Scientific for $600 million.

“Biobeat has completed what has been an elusive aim for a lot of – a clinically validated and FDA cleared cuff-less ABPM that has the potential to alter the use paradigm for measuring ambulatory blood strain. We see quite a few purposes for this expertise within the new subject of renal denervation (RDN) in addition to long run monitoring of post-cardiac process and CHF sufferers following discharge from the hospital,” mentioned Mr. Cohen. “I stay up for collaborating with the administration group to help the corporate’s mission to alter the way in which sufferers are monitored.”

Cohen presently serves on the boards of a number of public and enterprise capital backed progressive healthcare corporations, together with Kestra Medical Applied sciences (Nasdaq: KMTS); InspireMD (Nasdaq: NSPR); RxSight (Nasdaq: RXST), privately held Nalu Medical as chairman, Archimedes Vascular as chairman, Tulavi Medical as vice chairman, and Spectrum Vascular as an unbiased director. Mr. Cohen additionally serves as a enterprise associate with Paris-based Andera Companions and Beijing-based Sherpa Capital Companions.

The submit Biobeat Names Raymond W. Cohen Chairman of the Board first appeared on AI-Tech Park.